Pyloric Stenosis: Clinical Trials

19 trials for Pyloric Stenosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 unknown, 4 terminated, 3 completed, 2 active not recruiting. 19 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 219Unknown 7, Terminated 4, Completed 3, Active not recruiting 2, Recruiting 2, Not yet recruiting 1
Phase 17Unknown 5, Terminated 2

Follow Pyloric Stenosis: new trials by email Literature Review of Pyloric Stenosis trials Research Report on Pyloric Stenosis

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
BV+R-CHP - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin
Phase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University252025-09-012025-09-30
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Venetoclax, Azacitidine, Cytarabine - Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia
Phase 2Recruitingyuejun Liu322025-04-012025-06-10
Embryonal Tumor With Multilayered Rosettes
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection - Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Phase 2RecruitingUniversity of California, San Francisco702025-03-062026-06-29
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma
Phase 2Active not recruitingPatrick C. Johnson, MD282023-03-012026-01-29
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Phase 1 / Phase 2UnknownSun Yat-sen University542022-11-012023-12-14
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma
Phase 2TerminatedXencor, Inc.32022-04-152024-04-30
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
Phase 2TerminatedViracta Therapeutics, Inc.1022021-05-282025-07-28
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang302021-03-312021-03-15
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
Zanubrutinib, Tislelizumab - Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos
Phase 2UnknownRuijin Hospital402021-01-012021-03-30
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang332020-07-232021-03-15
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL
Lenalidomide, Cyclophosphamide, Doxorubicin - PTCL, NOS, AITL
Phase 1 / Phase 2UnknownThe First Affiliated Hospital with Nanjing Medical University912020-06-102020-06-16
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang1402020-04-242022-04-14
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
Sintilimab, Rituximab, Cyclophosphamide - EBV-Positive DLBCL, Nos
Phase 2UnknownThe First Affiliated Hospital with Nanjing Medical University552019-01-012019-11-29
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease
Fexinidazole, Placebo Oral Tablet - Chagas' Disease (Chronic) Nos
Phase 2CompletedDrugs for Neglected Diseases452017-11-132020-09-23
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
enzalutamide - Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma
Phase 2Active not recruitingAlliance for Clinical Trials in Oncology462016-09-142026-10-07
Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance
Autologous Hematopoietic Stem Cell Transplant - Complication of Transplanted Organ, Nos
Phase 2CompletedGary A Levy, O. Ont. MD. FRCP AGAF52015-12-012021-04-28
Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition
Ethanol, Heparin Lock, Normal Saline - Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter
Phase 1 / Phase 2TerminatedMayo Clinic392014-07-012017-12-12
Multiple Ascending Dose of BMS-911543
BMS-911543 - Cancer
Phase 1 / Phase 2TerminatedBristol-Myers Squibb982011-04-072019-07-31
PoC in Rheumatoid Arthritis With Methotrexate
BMS-582949, Placebo - Rheumatoid Arthritis, NOS
Phase 2CompletedBristol-Myers Squibb1212008-03-012015-10-12

Narrower conditions

Pyloric Stenosis, Hypertrophic (19)  ·  Lymphoma, Large B-Cell, Diffuse (4)  ·  Recurrence (2)  ·  Adenocarcinoma (1)  ·  Arthritis, Rheumatoid (1)  ·  Autoimmune Diseases (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Chagas Disease (1)  ·  Epstein-Barr Virus Infections (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Lymphoma, B-Cell (1)  ·  Neoplasms (1)  ·  Neuroectodermal Tumors, Primitive (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Salivary Gland Neoplasms (1)

Broader conditions

Digestive System Diseases (19)  ·  Gastric Outlet Obstruction (19)  ·  Gastrointestinal Diseases (19)  ·  Stomach Diseases (19)  ·  Immune System Diseases (8)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Hemic and Lymphatic Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Lymphatic Diseases (5)  ·  Lymphoproliferative Disorders (5)  ·  Lymphoma (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Lymphoma, B-Cell (3)

Interventions

Cyclophosphamide (4)  ·  Doxorubicin (3)  ·  Lenalidomide (3)  ·  Rituximab (3)  ·  Vincristine (3)  ·  Prednisolone (2)  ·  R-CHOP protocol (2)  ·  tislelizumab (2)  ·  4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo(1,2-f)(1,2,4)triazine-6-carboxamide (1)  ·  Azacitidine (1)  ·  Blood Specimen Collection (1)  ·  Cytarabine (1)  ·  Drug Therapy (1)  ·  Ethanol (1)  ·  Exportin 1 Protein (1)

Sponsors

Huiqiang Huang (3)  ·  The First Affiliated Hospital with Nanjing Medical University (3)  ·  Bristol-Myers Squibb (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Drugs for Neglected Diseases (1)  ·  Gary A Levy, O. Ont. MD. FRCP AGAF (1)  ·  Mayo Clinic (1)  ·  Patrick C. Johnson, MD (1)  ·  Ruijin Hospital (1)  ·  Sun Yat-sen University (1)  ·  University of California, San Francisco (1)  ·  Viracta Therapeutics, Inc. (1)  ·  Xencor, Inc. (1)  ·  yuejun Liu (1)

Countries

China (9)  ·  United States (8)  ·  Spain (4)  ·  France (3)  ·  Australia (2)  ·  Canada (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Czechia (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Malaysia (1)

Top investigators

Wei Xu, M.D., Ph.D. (2)  ·  Alan Ho, MD (1)  ·  Connor Johnson, MD (1)  ·  Darrel P Cohen, MD, PhD (1)  ·  Derek Hanson, MD (1)  ·  Gary A Levy, MD FRCP AGAF (1)  ·  Harold L Atkins, MD FRCP(C) (1)  ·  Huiqiang Huang, Professor (1)  ·  Michael Chiarella (1)  ·  Ryan Hurt, MD, PhD (1)  ·  Sabine Mueller, MD, PhD, MAS (1)  ·  Weili Zhao, PhD, MD (1)  ·  Yue-jun Liu (1)

Results publications

PMID 28576557, PMID 34049362, PMID 35867947, PMID 37530631, PMID 38218194

NIH funding

2016 (1)